Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

PRDO November 4, 2025

Perdoceo Education Corporation 3Q 2025 Earnings Call - Strong Enrollment Growth and St. Augustine Acquisition Drive Earnings Upside

Perdoceo Education Corporation reported third quarter 2025 results that surpassed expectations, driven by a 15.1% total student enrollment increase and contributions from the recent University of St. ...

  • Perdoceo reported third quarter net income of $39.9 million, or $0.60 per diluted share, with adjusted EPS of $0.65, up from $0.59 last year.
  • Total student enrollments increased 15.1% year-over-year, driven by 6.7% growth at CTU and the acquisition of University of St. Augustine.
  • CTU achieved its eighth consecutive quarter of enrollment growth, boosted by corporate student programs and prospective student interest.
  • +11 more takeaways
UPST November 4, 2025

Upstart Q3 2025 Earnings Call - Model Conservatism Dampens Volume Despite Strong Demand and AI Leadership

Upstart's Q3 2025 earnings reveal a company firing on most cylinders but constrained by its own AI model tightening in response to macroeconomic signals. Transaction volume growth fell short of expect...

  • Upstart grew transaction volume by 80% year-over-year and revenue by 71%, returning to solid profitability with GAAP net income up sixfold sequentially.
  • Applications surged over 30% quarter-over-quarter to over two million, the highest in more than three years, driven by marketing and cross-selling efforts.
  • Despite strong demand, model conservatism in Q3 reduced approval rates and increased interest rates, lowering conversion from 23.9% to 20.6%.
  • +9 more takeaways
PRCT November 4, 2025

PROCEPT BioRobotics Q3 2025 Earnings Call - Leadership Changes Fuel Focus on Utilization and Market Expansion Despite Macro Headwinds

PROCEPT BioRobotics reported robust Q3 2025 results with $83.3 million in revenue, underscoring strong U.S. capital system sales despite slower hospital purchasing cycles. New CEO Larry Wood, in his e...

  • PROCEPT BioRobotics achieved $83.3 million revenue in Q3 2025, up 43% YoY, with U.S. capital system sales driving growth despite cautious hospital capital spending.
  • CEO Larry Wood emphasizes procedure utilization as the top priority, initiating programs to accelerate time from system sale to first procedure and improve commercial execution.
  • New organizational changes include appointing Pooja Sharma as Chief Marketing and Strategy Officer and promoting Stephen Miguel to lead international operations, boosting focus on market-specific growth.
  • +12 more takeaways
ZETA November 4, 2025

Zeta 3Q25 Earnings Call - Accelerating Growth and AI Leadership with Athena Launch

Zeta reported a strong third quarter of 2025, marking its 17th consecutive beat-and-raise quarter. Revenue hit $337 million, up 28% year over year excluding political and LiveIntent, while adjusted EB...

  • Zeta achieved its 17th consecutive beat-and-raise quarter with Q3 2025 revenue of $337 million, up 28% year over year excluding political and LiveIntent revenues.
  • Adjusted EBITDA rose 46% year over year to $78 million, with margin expanding 320 basis points to 23.2%.
  • Free cash flow hit a record 14% margin, rising 83% compared to prior year, highlighting improved profitability alongside growth.
  • +17 more takeaways
FOA November 4, 2025

Finance of America Q3 2025 Earnings Call - Digital Innovation Drives Margin Expansion and Accelerated Growth

Finance of America reported a strong Q3 2025 driven by significant gains in operating performance and strategic balance sheet management. Adjusted net income doubled year-over-year to $33 million in t...

  • Finance of America reported a GAAP net loss of $29 million in Q3 2025 but posted $33 million in adjusted net income, doubling results from the prior-year quarter.
  • Year-to-date funded volumes increased 28% to approximately $1.8 billion compared to $1.4 billion in first nine months of 2024.
  • The company completed over $3 billion in securitizations during Q3, including a record nearly $2 billion proprietary securitization in September, its largest ever.
  • +7 more takeaways
ALGT November 4, 2025

Allegiant Travel Company Q3 2025 Earnings Call - Steady Margin Recovery and Strategic Fleet Optimization

Allegiant Travel reported a modest operating loss in Q3 2025, better than guidance, amid improved leisure demand and disciplined cost management. The airline is on track to end 2025 with approximately...

  • Allegiant reported a modest Q3 operating loss, better than guidance, supported by stronger leisure demand.
  • Full-year 2025 airline operating margin is expected around 7%, with EPS guidance raised to above $4.35 per share.
  • Boeing 737 MAX aircraft integration is progressing well; MAX fleet to comprise over 20% of ASMs in 2026 with 20-30% higher EBITDA per aircraft than A320 series.
  • +7 more takeaways
CDNA November 4, 2025

CareDx Q3 2025 Earnings Call - Robust 21% Revenue Growth and Strategic Advances Amid Flat Transplant Volumes

CareDx posted strong third-quarter 2025 results with revenue hitting $100.1 million, up 21% year-over-year, led by record volumes across testing services, patient and digital solutions, and lab produc...

  • CareDx delivered record third-quarter revenue of $100.1 million, a 21% increase year-over-year, and adjusted EBITDA of $15.3 million, more than doubling prior year.
  • Testing services revenue grew 19% to $72.2 million driven by 13% test volume growth across heart, kidney, and lung transplant monitoring.
  • Patient and digital solutions revenue rose 30% to $15.4 million, reflecting higher adoption of transplant pharmacy and digital tools.
  • +7 more takeaways
VCYT November 4, 2025

Veracyte 3Q 2025 Earnings Call - Decipher Prostate Test Drives Record Profitability and Accelerated Growth Outlook

Veracyte delivered a strong third quarter in 2025, reporting a 14% revenue increase to $132 million driven by a 26% volume growth in its Decipher prostate cancer test and 13% growth in the Affirma thy...

  • Veracyte’s Q3 revenue rose 14% year-over-year to approximately $132 million, driven by strong volume growth in core tests.
  • Decipher prostate cancer test volumes grew 26% year-over-year, marking 14 consecutive quarters with over 25% growth.
  • Affirma thyroid test volume grew 13%, supported by new account wins and increased utilization per customer.
  • +13 more takeaways
NGL November 4, 2025

NGL Energy Partners Q2 2026 Earnings Call - Water Solutions Segment Drives Record Growth and EBITDA Boost

NGL Energy Partners reported a solid Q2 2026, highlighted by record water volumes and a 30% jump in Grand Mesa pipeline volumes. Consolidated Adjusted EBITDA rose 12% year-over-year to $167.3 million,...

  • Q2 2026 consolidated Adjusted EBITDA climbed 12% year-over-year to $167.3 million, mainly driven by Water Solutions.
  • Water Solutions segment adjusted EBITDA increased 18% to $151.9 million, with physical disposal volumes growing 4% to 2.8 million barrels per day.
  • Total paid disposal volumes, including deficiency volumes, rose 14% to 3.15 million barrels per day compared to prior year quarter.
  • +11 more takeaways
SCOR November 4, 2025

comScore Q3 2025 Earnings Call - Cross-Platform Growth Offset by Large Client Shift, New Product Momentum Key

comScore reported a modest revenue increase to $88.9 million in Q3 2025, driven by strong double-digit growth in local and cross-platform measurement offerings. However, a notable strategy shift from ...

  • Q3 2025 revenues reached $88.9 million, a slight 0.5% increase year-over-year.
  • Local TV measurement showed strong double-digit revenue growth, driven by new business and renewals.
  • Cross-platform revenue grew 20.2% despite the headwind from a strategic shift by a large retail media client.
  • +10 more takeaways